Clinical Trial Update: AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)

View source ↗

Summary

A ClinicalTrials.gov entry for the AROMA2 study examines whether volatile biomarker profiles can augment assessment of esophagogastric cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Cancer
• Esophagogastric Junction Adenocarcinoma
• Gastric Cancer

Snippet

Sponsor: Imperial College London | Conditions: OESOPHAGO-GASTRIC CARCINOMA, Oesophageal Adenocarcinoma | Status: NOT_YET_RECRUITING